Purpose: Influenza vaccination of person living with HIV (PLWH) is a powerful means to tackle severe clinical outcomes. Few data on two doses of influenza vaccine in PLWH are available.
Research Design: To evaluate the immunogenicity and safety of two doses of vaccine as compared with single dose in PLWH, we searched Pubmed, Embase, and web of science databases for relevant articles (January 2009 to April 2023). Pooled SMD or RR and 95% CI were calculated.
Results: A total of 2436 participants from 14 studies were included. Compared to single dose influenza vaccine regimen, the pooled RR of seroprotection and seroconversion for two doses of vaccines was 1.14 (95%CI: 1.08–1.21) and 1.25 (95%CI: 1.16–1.34), respectively; the SMD of GMT was 0.42 (95%CI: 0.35, 0.49). Regarding safety, the fever risk in PLWH receiving two doses of vaccine was 3.42 fold higher than that of single dose vaccine, and the risk of myalgia had a quarter reduction. No serious vaccine-related adverse events were reported.
Conclusions: Collectively, two doses of the vaccine are associated with a better immunogenicity and an acceptable safety in PLWH. Two doses of the adjuvant vaccination might be a superior vaccination regimen.nation regimen.
BautistaEChotpitayasunondhTGaoZ, et al.Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med2010; 362: 1708–1719. DOI: 10.1056/NEJMra1000449.
4.
FinebergHV. Pandemic preparedness and response--lessons from the H1N1 influenza of 2009. N Engl J Med2014; 370: 1335–1342. DOI: 10.1056/NEJMra1208802.
5.
NunesMCCutlandCLMoultrieAMaternal Flu Trial Team. et al.Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV2020; 7: e91–e103. DOI: 10.1016/S2352-3018(19)30322-4.
6.
CooperCKleinMWalmsleySPhac Cihr Influenza Research Network. et al.High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1 (2009) and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin Trials2012; 13: 23–32. DOI: 10.1310/hct1301-023.
7.
NielsenABNielsenHSNielsenL, et al.Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. Vaccine2012; 30: 7067–7071. DOI: 10.1016/j.vaccine.2012.09.052.
8.
HatakeyamaSIwatsuki-HorimotoKOkamotoK, et al.Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults. Vaccine2011; 29: 9224–9228. DOI: 10.1016/j.vaccine.2011.09.106.
9.
LaglerHGrabmeier-PfistershammerKTouzeau-RömerV, et al.Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. PLoS One2012; 7: e36773. DOI: 10.1371/journal.pone.0036773.
10.
AbzugMJNachmanSAMuresanP, et al.Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. Clin Infect Dis2013; 56: 1488–1497. DOI: 10.1093/cid/cit057.
11.
FlynnPMNachmanSMuresanP, et al.Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. J Infect Dis2012; 206: 421–430. DOI: 10.1093/infdis/jis360.
12.
LeahyTRGoodeMLynamP, et al.HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children. Influenza Other Respir Viruses2014; 8: 360–366. DOI: 10.1111/irv.12243.
13.
Santini-OliveiraMCamachoLASouzaTM, et al.H1N1pdm09 adjuvanted vaccination in HIV-infected adults: a randomized trial of two single versus two double doses. PLoS One2012; 7: e39310. DOI: 10.1371/journal.pone.0039310.
14.
LaunayODesaintCDurierC, et al.Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis2011; 204: 124–134. DOI: 10.1093/infdis/jir211.
15.
BickelMvon HentigNWietersI, et al.Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2011; 52: 122-127. 2010/12/15. DOI: 10.1093/cid/ciq003.
16.
JamiesonDJHoneinMARasmussenSA, et al.H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet2009; 374: 451–458. DOI: 10.1016/s0140-6736(09)61304-0.
17.
ListerPReynoldsFParslowR, et al.Swine-origin influenza virus H1N1, seasonal influenza virus, and critical illness in children. Lancet2009; 374: 605–607. DOI: 10.1016/s0140-6736(09)61512-9.
18.
GayleHDHillGL. Global impact of human immunodeficiency virus and AIDS. Clin Microbiol Rev2001; 14: 327–335. DOI: 10.1128/cmr.14.2.327-335.2001.
DiazGranadosCADunningAJKimmelM, et al.Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med2014; 371: 635–645. DOI: 10.1056/NEJMoa1315727.
21.
SatanonSKiertiburanakulSBoonnakK, et al.A Prospective immunogenicity study of a quadrivalent inactivated influenza vaccine among persons with HIV with different levels of CD4 cell count. J Acquir Immune Defic Syndr (1999)2023; 93: 251–259. DOI: 10.1097/qai.0000000000003186.
22.
ZbindenDManuelO. Influenza vaccination in immunocompromised patients: efficacy and safety. Immunotherapy2014; 6: 131–139. DOI: 10.2217/imt.13.171.
23.
SagorKHAlAteeqMA. Beliefs, attitudes, and barriers associated with the uptake of the seasonal influenza vaccine among patients visiting primary healthcare clinics. Saudi Med J2018; 39: 690–696. DOI: 10.15537/smj.2018.7.22293.
24.
ChenYCZhouJHTianJM, et al.Adjuvanted-influenza vaccination in patients infected with HIV: a systematic review and meta-analysis of immunogenicity and safety. Hum Vaccin Immunother2020; 16: 612–622. DOI: 10.1080/21645515.2019.1672492.
25.
HigginsJPThompsonSGDeeksJJ, et al.Measuring inconsistency in meta-analyses. Br Med J2003; 327: 557–560. DOI: 10.1136/bmj.327.7414.557.
26.
PalmaPRomitiMLBernardiS, et al.Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. Biologicals2012; 40: 134–139. DOI: 10.1016/j.biologicals.2011.12.001.
27.
ManuelOPascualMHoschlerK, et al.Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis2011; 52: 248–256. DOI: 10.1093/cid/ciq104.
28.
HakimHAllisonKJVan De VeldeLA, et al.Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. Vaccine2012; 30: 879–885. DOI: 10.1016/j.vaccine.2011.11.105.
29.
MadhiSADittmerSKuwandaL, et al.Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. AIDS2013; 27: 369–379. DOI: 10.1097/QAD.0b013e32835ab5b2.
30.
SrivastavALuPJAmayaA, et al.Prevalence of influenza-specific vaccination hesitancy among adults in the United States, 2018. Vaccine2023; 41: 2572–2581. DOI: 10.1016/j.vaccine.2023.03.008.
31.
PallikkuthSDe ArmasLRPahwaR, et al.Impact of aging and HIV infection on serologic response to seasonal influenza vaccination. AIDS2018; 32: 1085–1094. DOI: 10.1097/qad.0000000000001774.
32.
TodorovT. [Incidence and causes for fracture of removable plaque prostheses]. Stomatologiia1988; 70: 17–23.
33.
LiuZPangCDengY, et al.Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults. Vaccine2023; 41: 4978–4985. DOI: 10.1016/j.vaccine.2023.05.055.
34.
DurierCDesaintCLuchtF, et al.Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults. AIDS2013; 27: 87–93. DOI: 10.1097/QAD.0b013e328359f27a.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
